Abstract Body

Background

AZD5582 (AZD) is a SMAC mimetic that reverses latency by activating the non-canonical NF-κB pathway and can trigger 3-4 logs transient viremia in ART-suppressed macaques. Yet, the reductions in the latent reservoir have been modest. Detailed analysis of the mechanisms is difficult to study due to low amplitude and fluctuating viral load signals. 

Methods

We compiled longitudinal measurements from published ART-suppressed, SIV-infected rhesus macaques treated with AZD alongside other interventions, e.g., SIV Env-specific monoclonal antibodies, the IL-15 superagonist N-803, and/or anti-CD8α depleting Ab MT807R1 (n=29). We fit an ensemble of mechanistic viral-dynamics models to plasma SIV RNA and SIV CA-DNA using a nonlinear mixed effect modeling framework and performed model selection using Bayesian information criteria and parameter identifiability. We used the parameter estimates from an ensemble of best models to infer AZD mode of action, and treatment response mechanisms. 

Results

The model ensemble recapitulated AZD5582-associated reactivation patterns in plasma SIV RNA and the dynamics of SIV DNA. Across best-fit models, AZD-reactivated cells exhibited reduced virion output and lower death rate by 32 – 89%. A transient, drug-induced refractory state after reactivation, during which cells were less responsive to additional AZD exposure, emerged as necessary to explain diminishing returns with closely spaced AZD dosing. In-silico dosing experiments predicted improved reservoir impact when inter-dose intervals were lengthened to allow exit from the refractory state. 

Conclusions

Mechanistic modeling explains the limited reservoir reduction despite robust AZD-mediated latency reversal: reactivated cells behave differently from fully productively infected cells and pass through a temporary refractory state. Introducing waiting periods between AZD courses may enhance overall effect size. The modeling framework provides a quantitative basis for optimizing AZD-based combinations and other drugs that target the non-canonical NF-κB pathway (e.g., Ciapavir) in future macaque and clinical studies.